Anisomelic acid | 59632-76-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Anisomelic acid
• 英文别名: (6E,10Z,14Z)-6,14-dimethyl-3-methylidene-2-oxo-3a,4,5,8,9,12,13,15a-octahydrocyclotetradeca[b]furan-10-carboxylic acid
• CAS: 59632-76-7
• 化学式: C₂₀H₂₆O₄
• 分子量: 330.4
• InChiKey: SORYERHBQFTRIK-XMLQBHOOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• PHARMACEUTICAL COMPOSITIONS OF ANISOMELIC ACID AND THE USE THEREOF
  申请人：Eriksson, John

  公开号：EP2895162A1

  公开（公告）日：2015-07-22
• Pharmaceutical compositions of Anisomelic acid and the use thereof
  申请人：ERIKSSON John

  公开号：US20150202180A1

  公开（公告）日：2015-07-23

  A pharmaceutical composition for anti-viral cancer treatment in mammals, comprising a therapeutically effective amount of Anisomelic acid or salts thereof. The pharmaceutical composition may comprise Anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof. A method of treating or preventing of cancer in a mammal, wherein the p53 pathway is deregulated by viral oncoproteins, is also provided.
• US9345687B2
  申请人：——

  公开号：US9345687B2

  公开（公告）日：2016-05-24
• [EN] PHARMACEUTICAL COMPOSITIONS OF ANISOMELIC ACID AND THE USE THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES D'ACIDE ANISOMÉLIQUE ET LEUR UTILISATION
  申请人：ERIKSSON JOHN

  公开号：WO2014033366A1

  公开（公告）日：2014-03-06

  A pharmaceutical composition for anti-viral cancer treatment in mammals,comprising a therapeutically effective amount of Anisomelic acid or salts thereof. The pharmaceutical composition may comprise Anisomelic acid or salt thereof in an oil-in-water emulsion, for example in an isotropic mixture of at least one oil and at least one surfactant or, alternatively, in a hydrophilic solvent and a co-solvents or surfactant or a combination thereof.A method of treating or preventing of cancer in a mammal, wherein the p53 pathway is deregulated by viral oncoproteins, is also provided.